Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 73Gastrointestinal 13Genitourinary 12Sarcoma 10Lymphoid 10Myeloid 9Head & Neck 5Dermatologic 5Thoracic 4Other hematologic neoplasm 3Breast 3Gynecologic 2Endocrine 2Plasma cell 1NET 1

Conditions

Breast Neoplasms 379Triple Negative Breast Neoplasms 61Ovarian Neoplasms 46Prostatic Neoplasms 35Colorectal Neoplasms 35Neoplasms 28Carcinoma, Non-Small-Cell Lung 27Endometrial Neoplasms 24Lung Neoplasms 22Neoplasm Metastasis 21Uterine Cervical Neoplasms 19Melanoma 18Stomach Neoplasms 17Pancreatic Neoplasms 16Squamous Cell Carcinoma of Head and Neck 15Carcinoma, Renal Cell 14Urinary Bladder Neoplasms 13Sarcoma 12Head and Neck Neoplasms 12Esophageal Neoplasms 11Colonic Neoplasms 10Advanced Breast Cancer 9Small Cell Lung Carcinoma 8Carcinoma, Transitional Cell 8Anatomic Stage I Breast Cancer AJCC v8 8Liver Neoplasms 7Kidney Neoplasms 7Cholangiocarcinoma 7Carcinoma, Hepatocellular 6Brain Neoplasms 6

Interventions

ulixertinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Temozolomide 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1Nivolumab 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Glioma × Breast × 30 days × Clear all
NCT03975959 2026-06-04

PROMESSE

Institut du Cancer de Montpellier - Val d'Aurelle

Phase NA Completed
426 enrolled
BreastCNS

Breast Neoplasms, Glioblastoma, Glioma

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05417594 2026-06-02

CERTIS1

AstraZeneca

Phase 1/2 Recruiting
695 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡